Shares of Heranba Industries Limited witnessed a notable rally of 4.83%, reaching ₹201.95, following the company’s announcement of its entry into the crop nutrition segment with the launch of two innovative products — Fentaamine and MycoHil. The development signals a strategic diversification aimed at strengthening the company’s position in the evolving global agriculture market.
The newly introduced Fentaamine is positioned as a next-generation bio-stimulant designed to enhance plant metabolic activity, improve tolerance to environmental stress, and significantly boost crop yields. Meanwhile, MycoHil has been developed as an advanced biofertilizer that enhances nutrient uptake efficiency, strengthens soil microbial ecosystems, and supports sustainable agricultural practices. Both products have been developed in collaboration with a leading American multinational company, combining international research expertise with Heranba’s strong manufacturing backbone.
The company’s foray into the crop nutrition domain is aligned with its broader “Vision 2026” strategy, which focuses on expanding its product portfolio and tapping into high-growth agricultural segments. As part of this roadmap, Heranba has set an ambitious revenue target of ₹2,500 crore for the current financial year. The company is also planning to expand its global footprint to more than 80 countries and is exploring the establishment of a subsidiary in Dubai to strengthen its presence in the Middle East and African markets.
In addition to geographic expansion, Heranba aims to leverage its existing infrastructure, including seven manufacturing facilities, to scale up operations. The company is also focusing on expanding its Contract Manufacturing Organization (CMO) business to improve capacity utilization and enhance brand visibility in international markets.
Commenting on the development, Managing Director R. K. Shetty stated that the crop nutrition sector is witnessing a strong compound annual growth rate (CAGR) of over 15% globally as well as in India. He emphasized that the company’s entry into this segment represents a natural strategic progression and expressed confidence in achieving accelerated growth over the next three years. He further highlighted that the integration of global research and development capabilities with Heranba’s manufacturing strengths would enable the company to deliver high-quality and sustainable solutions to farmers.
Heranba Industries Limited is primarily engaged in the production of synthetic pyrethroids and their intermediates and has an integrated presence across the agrochemical value chain, ranging from technical manufacturing to formulations. The company’s core focus remains on improving agricultural productivity while contributing to global food security initiatives.
However, despite the positive market response to the product launch, the company’s recent financial performance reflects certain challenges. Heranba reported a consolidated net loss of ₹23.25 crore in the third quarter of FY26, compared to a net loss of ₹10.19 crore in the corresponding period of the previous fiscal. Additionally, its net sales declined by 11.7% year-on-year to ₹301.37 crore during the quarter.
Overall, the launch of Fentaamine and MycoHil marks a critical step in Heranba’s growth trajectory, as it seeks to balance innovation-driven expansion with financial recovery in a competitive agrochemical landscape.
By
